ACADIA PHARMACEUTICALS INC 4

Accession 0001415889-17-000282

$ACADCIK 0001070494operating

View on SEC.gov Company Profile

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 7:06 PM ET

Size

29.9 KB

Accession

0001415889-17-000282

Insider Transaction Report

Form 4

Period: 2017-02-14

ACADIA PHARMACEUTICALS INCACAD

Moore Terrence O

EVP, CHIEF COMMERCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2017-02-14$19.61/sh+87,128$1,708,580→ 90,759 total
Exercise/Conversion
Common Stock
2017-02-15$19.61/sh+1,700$33,337→ 3,371 total
Exercise/Conversion
Common Stock
2017-02-16$19.61/sh+17,421$341,626→ 19,092 total
Exercise/Conversion
Common Stock
2017-02-16$34.45/sh+29,644$1,021,236→ 68,423 total
Exercise/Conversion
Stock Option (right to buy)
2017-02-14−12,747→ 7,649 total
Exercise: $19.61Exp: 2023-08-18→ Common Stock (12,747 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-02-14−74,381→ 55,223 total
Exercise: $19.61Exp: 2023-08-18→ Common Stock (74,381 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-02-15−1,700→ 53,523 total
Exercise: $19.61Exp: 2023-08-18→ Common Stock (1,700 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-02-16−17,421→ 36,102 total
Exercise: $19.61Exp: 2023-08-18→ Common Stock (17,421 underlying)
Sale
Common Stock
2017-02-14$39.69/sh−89,088$3,535,573→ 1,671 total
Sale
Common Stock
2017-02-15$39.65/sh−1,700$67,405→ 1,671 total
Exercise/Conversion
Common Stock
2017-02-16$27.20/sh+19,687$535,486→ 38,779 total
Sale
Common Stock
2017-02-16$39.88/sh−66,752$2,662,116→ 1,671 total
Exercise/Conversion
Stock Option (right to buy)
2017-02-16−19,687→ 13,125 total
Exercise: $27.20Exp: 2024-03-06→ Common Stock (19,687 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-02-16−29,644→ 90,356 total
Exercise: $34.35Exp: 2025-03-19→ Common Stock (29,644 underlying)

Footnotes (7)

[F1]Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
[F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
[F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
[F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
[F5]25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
[F6]25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
[F7]25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Documents

1 file

4
form4-02162017_040225.xmlPrimary

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001070494

Filing Metadata

Form type: 4
Filed: Feb 15, 7:00 PM ET
Accepted: Feb 16, 7:06 PM ET
Size: 29.9 KB

View on SEC.gov